Firmographics

Firmographics and identity

NameLegal nameWebsiteCompany typeFounded yearDescriptionShort descriptionOperating statusOwnership categoryHeadcount rangeakta.pro rank

Location

HQ, offices and markets served

HeadquartersMarkets servedOffices

Industry

Industry classification

KeywordIndustryNAICS codeSIC codeProduct category

Digital presence

Web, social and app footprint

Social media profiles

Business model

Revenue, pricing and go-to-market

GTM motionRevenue modelMarketing channelsDistribution channelsCost componentsPricing detailsGTM typeOffering type

Product offering

Products, brands and differentiators

BrandCore offeringDifferentiatorFunctional benefitProblem solvedQuantifiable outcomeProduct overviewProduct and service

Strategic signal

Partnerships and recent moves

Scale indicatorPartnershipRecent moveExpansion highlight

Company assessment

Strengths, risks and summary

PeersMarket positionStrengthsWeaknessesCompetitive moatKey risksKey highlightsCustomer concentration

Customer profile

Segments and customers

Named customersSegmentIdeal customer profile

Technology

Tech stack and AI capabilities

Technology focusedAPI detailIntegrationAI capabilityAI maturityApp detailFeatureCore technology

Financial estimate

Estimated financial performance

Revenue estimateValuation estimate

Management profile

Executive leadership team profiles

Number of profilesProfiles

Company hierarchy

Ownership structure and subsidiaries

Subsidiaries

Trust signal

Compliance and certifications

Compliance

Funding detail

Rounds, amounts and dates

Funding overviewFunding roundsInvestors

M&A and investment

Acquisitions and investments

M&AInvestment

Glaucoma UK

Full company profile

uuid004hw76

Namestring

Glaucoma UK

Websiteurl

Company typeenum

Private

Founded yearstring

-

Ownership categoryenum

akta.pro rankint

Markets served

Serves global market

No data

No data

No data

Differentiator

Functional benefit

Problem solved

No data

Market position

Customer concentration

Classification, Details

No data

API detail

Docs URL, Description

AI maturity

App detail

Has app

Core technology

Revenue estimate

Valuation estimate

Number of profiles

No data

No data

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Glaucoma UK

Company typePrivate
Founded-
Headquarters—
Headcount—
GTM type—
Offering—

Glaucoma UK firmographics

Firmographics

Name: Glaucoma UK
Website: https://glaucoma.uk
Company type: Private
Ownership category
akta.pro rank

Glaucoma UK technology and API

Technology

API detail

API docs
API detail

Core technology

AI maturity

App detail

Glaucoma UK competitors and assessment

Company assessment

Market position

Customer concentration

Glaucoma UK financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Glaucoma UK leadership team

Management profile

Number of profiles

Glaucoma UK funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Glaucoma UK M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glaucoma UK

When was Glaucoma UK founded?

Glaucoma UK was founded in -1.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Live signals

Stock TitanAug 10, 2026Artelo Doses First Patient in Phase 2 Glaucoma TrialArtelo Biosciences announced the enrollment of the first patient in its Phase 2 DREAM clinical trial, which evaluates the oral synthetic cannabinoid ART27.13 for treating glaucoma and ocular hypertension. The investigator-led study is funded by Glaucoma UK and the HSC R&D Division, with initial results anticipated in the fourth quarter of 2026. This expansion into ophthalmology aims to determine if ART27.13 can safely lower intraocular pressure without central nervous system side effects.GlobeNewswireMar 18, 2026Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma PatientsArtelo Biosciences entered a third-party funded clinical study with Belfast Health and Social Care Trust to evaluate ART27.13 in glaucoma patients. The study, funded by Glaucoma UK and HSC R&D, is expected to enroll its first patient in Q2 2026. The company aims to expand ART27.13's therapeutic profile beyond cancer-related anorexia.